Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Recruiting

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

A Prospective Cohort to Evaluate the Ability of Different Body fLuid-derived Approaches to Detect EArly-stage Cancers Among High-risk Individuals

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Recruiting
Study type
Interventional
Start
16 March 2026
Expected end
June 2030
Enrollment
5,909 participants
Sites
1
Primary outcomes
sensitivity of techniques derived from body fluids in the detection of any invasive cancer
Sponsor type
Academic / other
Results posted
No
Last update
30 March 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.